Purpose: To investigate whether the 2 subtypes of advanced age-related macular degeneration (AMD), choroidal neovascularization (CNV), and geographic atrophy (GA) segregate separately in families and to identify which genetic variants are associated with these 2 subtypes.
atrophy of the macular neurosensory cells, whereas CNV often presents with acute vision loss and involves growth of abnormal choroidal vessels under the macula. Both advanced forms can be found in the same patient; GA and CNV can occur in the same eye or a patient may have GA in one eye and CNV in the other. Although there are also some predisposing pathophysiological changes in the extracellular matrix of the macula that are seen in both types of AMD, 3 it is unclear what causes eyes with early or intermediate AMD to progress to one advanced subtype or the other. Some differences given the effects of environmental risk factors, such as hypertension and cigarette smoking, on the development of neovascular versus nonneovascular AMD have been suggested. 4 -6 However, these environmental risk factors alone do not explain the entire difference in development of the 2 subtypes.
The genetic predisposition of overall AMD has been demonstrated clearly, 1, 7 and genetic association studies have been successful in uncovering common variants at several loci that account for this. 8 -22 These case-control association studies commonly have a combination of patients with GA and patients with CNV together as advanced cases. Subgroup analyses performed as part of some of these investigations generally have not found significant differences in the risk allele frequencies for CNV versus GA, 12, 15, 17, 18, 20 which may be the result of limited power, given the relatively small number of patients with GA in these investigations. However, in the subgroup analyses for the largest genome-wide association study (GWAS) performed to date and in a candidate gene study performed by the authors' group in a large sample, the ARMS2/HTRA1 locus (rs10490924) was associated with a greater risk of CNV compared with GA. [21] [22] [23] Interestingly, no other loci have been proven to predispose specifically to one of the advanced forms. Herein, new information is reported and previous analyses of this subphenotype difference are expanded in the following ways: (1) including novel evidence for sibling correlation, (2) investigating more than 6 million additional loci using genome-wide data with improved imputation methods based on the 1000 Genomes Project, 24 (3) adding in-depth analyses of the single nucleotide polymorphisms (SNPs) associated with overall advanced AMD, including the recently reported FRK/COL10A1 and VEGFA loci, 25 and (4) incorporating additional replication samples. The purposes of this study were to determine whether development of CNV versus GA is heritable and to identify genetic variants that may explain differences in risk of CNV versus GA with an unbiased method of examining genetic loci across the genome.
Patients and Methods
The methods used in this study conformed to the tenets of the Declaration of Helsinki. Informed consent was obtained from all participants, and this work complied with the Health Insurance Portability and Accountability Act. Institutional review board/ ethics committee approval was obtained.
Sibling Correlation: Heritability
To determine the heritability of GA and CNV, a sibling correlation study was performed. A sibling correlation analysis examines whether siblings are more likely to have the same subtype of advanced AMD than what would be expected by chance alone, if there were no shared genetic risk factors that contribute to the subtype development. Participants for this analysis were derived from the Family Study of AMD. 26, 27 Families with 2 or more siblings reported to have AMD (large drusen, GA, or CNV) were recruited from the AMD database of the principal investigator (JMS), from other ophthalmologists throughout the country, from the Age-Related Eye Disease Study Ancillary Study, and through various media (newspapers, newsletters, brochures). All siblings were assessed with ocular examination and fundus photography. For this analysis, 2 siblings were chosen from each family in the Family Study of AMD database. Both siblings had either GA or CNV in at least 1 eye, and if bilateral advanced disease was present, they could not have GA in one eye and CNV in the other eye. If there were only 2 siblings with advanced AMD in the family that met the criteria, those 2 siblings were chosen. If the family had more than 2 siblings with advanced AMD who met the criteria, a computer-generated randomization algorithm selected the 2 siblings. The observed proportion of sibling pairs were calculated (1) who both had GA as their worse eye grade, (2) who both had CNV as their worse eye grade, and (3) in which one sibling had GA as the worse eye grade and the other sibling had CNV as the worse grade. The expected proportions for these 3 categories were calculated based on the number of individuals with each eye grade, assuming that the occurrence of the 2 subphenotypes of CNV and GA was not heritable. The distributions of the observed versus expected proportions of the 3 sibling pair categories were compared using the chi-square test.
Because the ARMS2/HTRA1 locus has been shown to contribute to the potential heritability of the 2 subphenotypes, the expected proportions for the 3 sibling pair categories also were calculated controlling for the ARMS2/HTRA1 genotype. For this CNV ϭ choroidal neovascularization; GA ϭ geographic atrophy. P ϭ 4.2ϫ10 -5 . The P value for the chi square test was calculated by comparing the difference between the observed and expected distributions of siblings concordant for the subtype of advanced age-related macular degeneration in their worse eye. The expected distributions were calculated assuming no heritability of the 2 subphenotypes of CNV and GA and were based solely on the number of individuals with each eye grade.
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analysis, participants were divided into 3 groups based on their observed ARMS2/HTRA1 genotype group (GG, TG, and TT). Within each genotype group, each participant's phenotype then was reassigned randomly to CNV or GA while preserving the observed proportion of participants with CNV versus GA within each genotype group. This random assignment was performed with a computer-generated algorithm. The proportion of siblings in each category then was recalculated. This analysis was carried out to assess how much of the sibling correlation that was observed for advanced AMD subtype could be explained by the ARMS2/HTRA1 genotype.
Genome-Wide Association Meta-analyses
Discovery Sample Description. For the GWAS, the cases and controls were derived from the Tufts/Massachusetts General Hospital (MGH) GWAS Cohort Study 21 ; the Michigan, Mayo, AgeRelated Eye Disease Study, the Pennsylvania (MMAP) Cohort Figure 3 . Manhattan plots for genome-wide association analyses of the discovery cohort comparing (A) participants with geographic atrophy (n ϭ 819) with participants with choroidal neovascularization (n ϭ 1775), (B) participants with geographic atrophy to participants with no age-related macular degeneration (AMD; n ϭ 4134), and (C) participants with choroidal neovascularization to participants with no AMD. The y-axes of the plots are truncated at 1ϫ 10 -20 . -log 10 (P) ϭ negative logarithm (base 10) of the single nucleotide polymorphism's P value; ARMS2/HTRA1 ϭ age-related maculopathy susceptibility 2/HtrA serine peptidase 1; CFH ϭ complement factor H; CFB ϭ complement factor B; PECI ϭ peroxisomal D3,D2-enoylCoA isomerase; C3 ϭ complement component 3; CFI ϭ complement factor I.
Study
22 ; as well as controls from the Myocardial Infarction Genetics Consortium (MIGen) 28 and the Genetic Association Information Network (GAIN) Schizophrenia Study. 29 Information on the publicly available MMAP and GAIN dataset sources is available in Appendix 1 (available at http://aaojournal.org). All patients were of European ancestry. For the Tufts/MGH GWAS Cohort Study, AMD grade was assigned based on fundus photography and ocular examination (Clinical Age-Related Maculopathy Grading System [CARMS] advanced AMD grades 4 and 5). 30 The CARMS grade 4 is defined as either GA with involvement of the macular center or noncentral GA at least 350 m in size. The CARMS grade 5 is defined as exudative AMD including nondrusenoid pigment epithelial detachments, serous or hemorrhagic retinal detachments, CNV with subretinal or subpigment epithelial hemorrhage or fibrosis, or scarring consistent with the treatment of AMD. If a patient had evidence of both GA and CNV in the same eye, they were classified as having grade 5 (CNV) in that eye. The final designation of grade for each participant was based on the highest grade in either eye. Therefore, a patient who had grade 4 (GA) in one eye and a grade 5 (CNV) in the other eye was designated as having grade 5 (CNV) for the main analysis. Examined participants without AMD were unrelated to cases, were 60 years of age or older, and were defined as individuals without macular degeneration, categorized as CARMS stage 1, based on fundus photography and ocular examination. Only MMAP cases with GA or CNV were included in the analysis; early and intermediate AMD cases were excluded. The MIGen controls were included in a previous GWAS study and were described in detail. 21 Shared controls from the GAIN Schizophrenia Study have also been previously described. 29 The combined Tufts/MGH, MMAP, MIGen, and GAIN dataset is referred to as the Tufts/MMAP/ MIGen/GAIN (TMMG) sample. This dataset has been described previously in further detail.
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Genotyping. The Tufts/MGH and MIGen samples were genotyped at the Broad Institute and National Center for Research Resources Center for Genotyping and Analysis using the Affymetrix SNP 6.0 GeneChip (AFFY 6.0, 909622 SNPs, Affymetrix, Santa Clara, CA). 31 Shared controls from the GAIN study obtained from the database of Genotypes and Phenotypes (dbGaP) also were genotyped by using the Affymetrix SNP 6.0 GeneChip. The MMAP samples obtained from dbGaP were genotyped on the Illumina HumanCNV370v1 Bead Array (ILMN 370, 370404 SNPs; Illumina, Inc., San Diego, CA). 22 All samples included in this study met quality-control measures as described previously. 21, 22 For the meta-analysis of GWAS, only high-quality imputed genotypes (information (INFO) scores Ͼ0.6) and minor allele frequency Ͼ0.01 were included. 25 The INFO score is a measure of imputation reliability. A consensus set of 6 036 699 high-quality SNPs from each imputed dataset was analyzed by PLINK using a generalized linear model controlling for the genotyping platform and genetic ancestry based on principal component analysis by EIGENSOFT. The imputed genotypes were coded by the allele dosage for each SNP in the analysis.
Genome-Wide Association Study Meta-analyses. Three main GWAS analyses were performed. First, individuals who had CNV in at least 1 eye were compared with those with GA in at least 1 eye. If a patient had GA in one eye and CNV in the contralateral eye, they were classified as a CNV case for the primary analyses. Second, individuals who had GA in at least one eye and no CNV in either eye (cases) were compared with individuals without any signs of AMD (controls). Finally, individuals who had CNV in at least 1 eye (cases) were compared with individuals without any signs of AMD (controls). It is possible that some of these CNV cases had GA in their contralateral eye. Also each of these analyses was performed adjusting for age at ascertainment and separately in men and women. To determine if the inclusion of patients who had CNV in one eye and GA in the other eye as CNV cases in the main analyses affected the association results, a sensitivity analysis was performed. The sensitivity analysis consisted of repeating the analysis with the subset of patients with grades available for both eyes and excluding the patients who had CNV in one eye and GA in the other eye. Patients with CNV and GA in the same eye were not excluded for this sensitivity analysis because sufficiently detailed phenotyping information was not available for most patients to isolate these cases. For novel associations, the P value threshold for significance in the GWAS was P ϭ 5ϫ10 -8 . For SNPs in the 13 loci that have been associated previously with overall advanced Ophthalmology Volume xx, Number x, Month 2012 AMD, a P value threshold for significance of 0.0038 was determined by the Bonferroni correction method.
Replication Samples and Genotyping. Replication of SNPs with the smallest P values from the CNV versus GA and CNV versus no AMD analyses was pursued in 10 independent cohorts from Johns Hopkins University, Columbia University, Washington University, Genentech, the Rotterdam Study, Centre for Eye Research Australia, an independent replication sample from Tufts/ MGH, Hôpital Intercommunal de Creteil, the Queen's University of Belfast, and Complications of AMD Prevention Trial. 25, 32 All replication studies applied similar criteria for the diagnosis of cases. The SNPs that met genotype quality control criteria in replication cohorts were tested for association with a generalized linear model in PLINK. An additive model was used for each SNP (0, 1, or 2 minor alleles). A combined analysis was conducted for the results of top SNPs in all participating cohorts using CochranMantel-Haenszel pooling of the odds ratios (ORs) and a fixed effects model with inverse-variance weighting.
Results

Sibling Correlation: Heritability
From the 390 families that are part of the Family Study of AMD, 209 had sibling pairs who met the inclusion criteria for this sibling correlation analysis. The other 181 families did not meet criteria because they did not have 2 siblings with GA or CNV (n ϭ 145) or at least 1 of the siblings had GA in one eye and CNV in the other eye (n ϭ 36). The distribution of gender in the 209 sibling pairs was in line with the overall female predominance in the Family Study of AMD: 15% were brother-brother pairs, 39% were sister-brother pairs, and 46% were sister-sister pairs. The difference between the observed and expected distributions of siblings concordant for the subtype of advanced AMD in their worse eye was statistically significant (P ϭ 4.2ϫ10 -5 ; Table 1 ). This means that, if CNV develops in one sibling, the other sibling is more likely to have CNV than GA if advanced AMD develops. Conversely, if GA develops in one sibling, the other sibling is more likely to have GA than CNV if advanced AMD develops. This supported the rationale for continuing the analyses to look for genetic variants that exert a differential effect on the risk of GA as compared with CNV.
Genome-Wide Association and Replication Analyses
Choroidal Neovascularization versus Geographic Atrophy. The TMMG dataset contained 819 participants with GA and 1775 participants with CNV (the discovery cohort). Figure 1 (available at http://aaojournal.org) shows a plot of the first 2 principal components from this analysis. Principal components analysis is a way to correct for population stratification (allele frequency differences between cases and controls because of systematic ancestry differences) that can cause spurious associations in genetic association studies. 33 The principal components analysis for genetic association studies takes the genotype data from each individual to infer their genetic ancestry. It plots this genetic ancestry by individual principal components, or axes of genetic variation, to determine if the cases and controls differ in their genetic ancestry. Review of the first 2 principal components derived from the genetic data showed no obvious difference between cases and controls, suggesting absence of any significant population stratification. Meta-analysis of GWAS P values were plotted in quantile-quantile plots (Fig 2A, available at http://aaojournal.org). Little statistical inflation was observed in the distribution of the association statistic (inflation factor gc ϭ 1.014). Figure 3A shows a Manhattan plot for this analysis. In the Manhattan plot, each dot represents 1 SNP tested in the GWAS. Each dot, or SNP, is plotted according to its location along the chromosomes of the human genome (horizontal axis) and its P value in the GWAS analysis (vertical axis). The higher the dots, the stronger the genetic association. The red line indicates the genome-wide significance threshold of 5ϫ10 -8 . The ARMS2/HTRA1 locus is the only one to meet this significance threshold on the Manhattan plot of the GWAS analysis for CNV versus GA. Table 2 includes the most statistically significant SNPs for independent loci from the GA versus CNV comparison for new and previously reported AMD SNPs. A statistically significant association signal was observed at the ARMS2/HTRA1 locus (rs10490924; P ϭ 4.3ϫ10 -9 ). Figure 2B (available at http:// aaojournal.org) shows the quantile-quantile plot of the GWAS meta-analysis results after removal of the ARMS2/HTRA1 locus where the line became flattened to gc ϭ 0.999. Removal of the ARMS2/HTRA1 locus was done to visualize more easily if there were any other loci that are significantly associated. No other loci were associated at a genome-wide significant P value (Ͻ5ϫ10 -8 ). However, several variants reached a significance level of 5.5ϫ10 -6 to 1.4ϫ10 -6 , including SNPs in KCTD10 and NFATC2 and SNPs near QSER1, BC017935, LILRA4, NUDT4, RASA1, ADARB2, and UTP18. After adjusting for age at ascertainment, the results were not significantly different, with ARMS2/HTRA1 again being the only locus to achieve genome-wide significance (OR, 1.48; P ϭ 3.6ϫ10 -9 ). None of the other SNPs that previously were associated with overall AMD were significantly associated in CNV versus GA analysis.
When the contribution of the ARMS2/HTRA1 locus to sibling correlation was evaluated for AMD subtype, a small amount of the excess sibling correlation could be explained by genetic variation in this region (Table 1) . For example, the proportion of sibling pairs expected to be concordant for GA assuming no heritability was 7.7%, and the observed proportion was 13.8%, or a 6.1% difference in the proportion observed versus expected. This means that there must be shared genetic or environmental factors, or both, that increase the chance of 2 siblings having the same subtype of AMD (in this case, GA) by 6.1 percentage points over what would be expected if there were no genetic or environmental factors at play. When the effect of the ARMS2/HTRA1 locus was controlled, the proportion of the sibling pairs expected to be concordant for GA was 8.1%, which explained 0.4% (8.1% minus 7.7%) of the 6.1% difference. If 2 siblings both have at least 1 T allele at the ARMS2/HTRA1 locus, CNV is more likely than GA to develop in both, although genetic similarity at this locus accounts for a small part of the reason that the siblings are more likely to share the same AMD subtype. The replication sample consisted of independent datasets not included in the above analyses. These were included to confirm the associations detected in the discovery dataset. There were 4515 participants with CNV, 868 participants with GA, and 15 240 participants with no AMD in these additional datasets. In these samples, rs10490924 was examined further ( Table 3 ). The direction of the effect for rs10490924 was consistent in most of the replication samples, with a final meta-analysis OR of 1.38 (95% confidence interval [CI], 1.27-1.51; P ϭ 7.4ϫ10 -14 ). Meta-analysis for the replication datasets alone yielded an OR of 1.32 (95% CI, 1.18 -1.48; P ϭ 1.8ϫ10 -6 ). The T allele at rs10490924 was associated with a higher risk of CNV compared with GA. When meta-analysis of independent datasets is used to estimate a combined effect, confirmation is needed that the effects found in the individual studies are similar enough that one can be confident that a combined estimate will be a meaningful description of the set of studies. The estimates for the effect of each SNP of individual studies will vary by chance, and some variation is expected. When heterogeneity is present among studies, it means that there is more variation than would be expected by chance alone, and a combination of these studies using meta-analysis techniques is not valid. There was no evidence for heterogeneity in the meta-analyses for rs10490924 with P values for the Q test of heterogeneity of 0.07 (I 2 ϭ 41.7) and 0.07 (I 2 ϭ 42.7) for the analyses, including and excluding the discovery cohort, respectively. That is, heterogeneity among studies was not present to a statistically significant degree (P Ͻ 0.05).
In the discovery cohort, a region on chromosome 11 that contained several SNPs in LD with P Ͻ 5ϫ10 -6 also was detected, including rs4755455 (P ϭ 2.1ϫ10 -7 ; Table 2 ). In ageadjusted analyses, the association with rs4755455 also was consistent with an OR of 1.59 (P ϭ 3.1ϫ10 -7 ). This association of rs4755455 with advanced AMD subtype, however, was not consistent across the replication samples, yielding meta-analysis P values of 0.003 and 0.63 for the analyses including and excluding the discovery cohort, respectively (Table 3 ). There was evidence for heterogeneity in the meta-analysis for rs4755455 with a P Table 4 . Ten most highly associated SNPs from the genome-wide association analyses comparing (A) participants with choroidal neovascularization (CNV) to participants with no age-related macular degeneration and (B) participants with geographic atrophy (GA) to participants with no age-related macular degeneration AMD ϭ age-related macular degeneration; BP ϭ base position; CHR ϭ chromosome; CNV ϭ choroidal neovascularization; EA ϭ Effective allele (frequency and odds ratios are based on this allele); Freq ϭ frequency, GA ϭ geographic atrophy; INFO ϭ information content; L95 ϭ lower 95% confidence interval; OR ϭ odds ratios; SNP ϭ single nucleotide polymorphism; U95 ϭ upper 95% confidence interval. *The INFO score for rs2230199 is less than the QC threshold we used for INFO Score for this analysis. We present the result for this SNP specifically because it is the one that has been previously reported to be associated with overall advanced AMD. Variant rs163494 upstream from C3 had an INFO score Ͼ0.6, is in linkage disequilibrium with rs2230199, and was associated with P ϭ 3.8ϫ10 -12 for CNV vs. no AMD and P ϭ 1.2ϫ10 -11 for GA vs. no AMD.
value for Q test of heterogeneity of 0.007 (I 2 ϭ 58.7). When there is heterogeneity present in a meta-analysis, one approach is to incorporate it into a random effects model that involves the assumption that the effects being estimated in the different studies are not identical, but follow a distribution. In a random effects meta-analysis, the P value for the association to rs4755455 was not significant (P ϭ 0.75). Table 2 also shows the meta-analysis GWAS results comparing participants with GA with participants with CNV for SNPs previously associated with overall advanced AMD. Apart from ARMS2/HTRA1, none of the variants in other loci that previously were associated with advanced AMD had a statistically significant differential effect on risk of CNV versus GA. The estimates of the OR for the comparison of the 2 subtypes of AMD in the GWAS were more than 1.10 for variants in the C2, CETP, and TIMP3 loci (OR estimates, 1.13-1.30). To further explore these possible small differences in effect of the genes on CNV versus GA, the previously associated loci with additional data, when available, from the replication cohorts were examined, and there was no statistically significant association in this larger dataset other than the ARMS2/HTRA1 locus association (Table 3) . With the additional replication data, C2 and TIMP3 maintained ORs of more than 1.10, but still did not achieve statistical significance.
For the Tufts/MGH dataset, bilateral eye grades were available, and additional sensitivity analysis was performed in which cases with CNV in one eye and GA in the other eye were excluded. This dataset included 481 patients with GA and 858 patients who had CNV in at least one eye, of which 221 had CNV in one eye and GA in the other eye. With exclusion of these mixed cases from the analysis, there was no significant change in the results, apart from a generalized decrease in the P values resulting from decreased power expected with removal of 25% of the CNV cases. For rs10490924, the OR was 1.46 (95% CI, 1.24 -1.71; P ϭ 4.2ϫ10 -6 ) including the mixed cases and 1.38 (95% CI, 1.16 -1.64; P ϭ 2.5ϫ10 -4 ) excluding the mixed cases.
Geographic Atrophy versus No Age-Related Macular Degeneration and Choroidal Neovascularization versus No AgeRelated Macular Degeneration.
Most Highly Associated Single Nucleotide Polymorphisms from Genome-Wide Association Study. For the GA versus no AMD analysis, the TMMG dataset contained 819 participants with GA and 4134 participants without AMD. Figure 3B shows a Manhattan plot for the analysis comparing participants with GA with participants without AMD. As expected, several SNPs previously associated with advanced AMD (CFH, CFB, ARMS2/HTRA1, and C3) had P values less than the genome-wide significance threshold of 5ϫ10 -8 , as indicated by the red line on the plot. In addition, a region on chromosome 6 was detected that contained 3 SNPs with P Ͻ 1ϫ10 -10 , including rs582301 in the PECI gene (OR, 4.77; P ϭ 3.2ϫ10 -11 ). Table 4 lists the most statistically significant SNPs for independent loci from this GWAS analysis; adjustment for age at ascertainment showed similar results. Other than the known genes and PECI, the following variants had P values that were suggestive of association: rs2842992 (near SOD2) with P ϭ 3.4ϫ10 -7 , rs1789110 (near MBP) with P ϭ 4.2ϫ10 -7 , and rs722782 (near C80rf42) with P ϭ 1.9ϫ10 -6 . Because rs582301 in PECI was rare and imputed, direct genotyping was pursued in a subset of the sample to try to validate the imputation. In a subset of 21 individuals for whom imputation predicted the genotype AG, only 2 actually had this genotype on direct genotyping, suggesting this association is possibly the result of imputation error.
For the CNV versus no AMD analyses, the TMMG dataset contained 1775 participants with CNV and 4134 participants without AMD. Figure 3C shows a Manhattan plot for the analysis comparing participants with CNV with participants without AMD. Only SNPs that previously had been associated with advanced AMD-CFH, CFI, CFB, ARMS2/HTRA1, and C3-had P values less than the genome-wide significance threshold of 5ϫ10 -8 , as indicated by the red line on the plot. Table 4 shows the most statistically significant SNPs in independent loci from this analysis. Adjustment for age at ascertainment showed similar results. Regions on chromosomes 8 and 18 were detected with several SNPs with P Ͻ 5ϫ10 -7 , including rs35691538 (near TRIB1) and rs8091635 (near BRUNOL4), P ϭ 1.3ϫ10 -7 and P ϭ 1.7ϫ10 -7 , respectively. To investigate these regions further, replication was attempted (Table 3) . For rs8091635, the direction of effect was not consistent in the replication sample, and after meta-analysis, the P value decreased to 2.2ϫ10 -5 . There was heterogeneity present in the meta-analysis with P ϭ 0.008 for the Q test (I 2 ϭ 65.6). In a random effects meta-analysis, the P value for the association to rs8091635 was 0.23. Because the minor allele of the other SNP rs35691538 is rare and this SNP was not well imputed in replication of GWAS datasets, no other replication cohorts with available Table 5 shows a side-by-side comparison of the results for the GA versus no AMD and the CNV versus no AMD comparisons for loci previously associated with overall advanced AMD. Significant association signals were observed (below the predetermined threshold for significance of 0.0038) for the CNV subtype versus no AMD comparison at SNPs in loci previously associated with overall advanced AMD. These included LIPC (P ϭ 2.4ϫ10 -4 ), TIMP3 (P ϭ 8.0ϫ10
-5 ), CETP (P ϭ 6.5ϫ10 -6 ), FRK/COL10A1 (P ϭ 4.1ϫ10 -5 ), VEGFA (P ϭ 2.0ϫ10 -4 ), and ABCA1 (P ϭ 0.002). For the GA subtype versus no AMD comparison, significant association signals also were observed at SNPs in many of the loci previously associated with overall advanced AMD. Those SNPs that met the predetermined threshold for significance of 0.0038 for known SNPs included VEGFA (P ϭ 0.002), COL8A1 (P ϭ 0.0036), and FRK/COL10A1 (P ϭ 1.4ϫ10 -4 ). For the ARMS2/HTRA1 locus, the OR (95% CI) for GA versus no AMD was 2.52 (2.23-2.83), and the OR (95% CI) for CNV versus no AMD was 3.67 (3.33-4.05). Of note, apart from this ARMS2/ HTRA1 locus, the magnitude of the ORs related to the other genes for the 2 advanced subtypes were similar with overlapping CIs.
Gender-Specific Analyses. Genome-wide association analyses were performed for each gender separately for the CNV versus GA, GA versus no AMD, and CNV versus no AMD comparisons and did not reveal any additional novel associations. For the ARMS2/HTRA1 locus in the CNV versus GA comparison, the association was similar in both men and women with an OR of 1.52 (P ϭ 1.57ϫ10 -6 ) in the women-only analysis and an OR of 1.39 (P ϭ 0.001) in the men-only analysis, showing a larger effect of this locus relative to other genetic loci on CNV versus GA in both groups.
Discussion
Data from the sibling analysis provides novel evidence for sibling correlation of the major subphenotypes of AMD-CNV and GA-which can reflect shared genetic or environmental risk factors, or both. 34, 35 These results could be used to educate patients who have a family history of one of the advanced forms of AMD about the increased likelihood of developing the same form as their siblings. Although this report provides evidence for an increased likelihood for the same advanced AMD subtype among siblings, there can be substantial AMD phenotypic heterogeneity in family members with AMD, and it is not uncommon to have several AMD subphenotypes in 1 family. 36 Having established excess sibling correlation of these subphenotypes and having demonstrated a difference between CNV and GA genetic susceptibility for the ARMS2/ HTRA1 locus previously, 23 this analysis of GWAS data from a larger GWAS meta-analysis was undertaken to try to uncover additional loci associated with an increased risk of one advanced form over the other. The aggregate replication cohort sample was the largest to date at the initiation of analyses for this type of subphenotype analysis, with 4515 CNV cases, 868 GA cases, and 15 240 controls with no AMD. A definitive genome-wide significance of the previously suggested increased risk for CNV was demonstrated compared with GA for the T allele of the ARMS2/HTRA1 locus (OR, 1.38; P ϭ 7.4ϫ10 -14 ). 23, [37] [38] [39] The T allele at the ARMS2/HTRA1 locus has previously been well established as a risk factor for overall advanced AMD defined as GA, CNV, or both in either eye. The findings from this study suggest that although the T allele increases the risk of developing CNV, GA, or both, it increases the risk of developing CNV to a greater degree than the risk of developing GA in patients who develop advanced AMD. Based on these results (OR, 1.38), for each T allele a participant had at the ARMS2/HTRA1 locus, their odds of having CNV in either or both eyes was 38% higher than their odds of having only GA in either or both eyes at the time of phenotype ascertainment, which occurred after they already had advanced AMD (GA or CNV) in at least 1 eye. Adjusting for age at AMD ascertainment showed a similar result. The GWAS analyses for each gender separately also demonstrated similar results in men and women.
The patients in this study who were designated CNV cases were primarily patients who only had CNV in one or both eyes and no signs of GA in either eye. However, there were some patients who had CNV in one eye and GA in the other eye. Inclusion of these mixed participants did not alter the results. Therefore, even in patients who might currently have GA in one eye, each T allele they have confers an increased odds of CNV developing in the second eye compared with a similar patient with GA who does not have that allele.
There are some underlying biological mechanisms that could explain why the ARMS2/HTRA1 locus confers this increased risk for CNV. There is evidence for a role of the HTRA1 protein in the angiogenesis involved in CNV 40 ; the HTRA1 protein has been localized to vascular endothelium and may favor neovascularization by enhancing degradation of extracellular matrix components or by binding to transforming growth factor-␤, an angiogenic factor. 41, 42 However in this study, the ARMS2/HTRA1 locus accounts for only a small amount of the excess sibling correlation for advanced AMD subtype, suggesting there are additional genetic or environmental factors, or both, including smoking and nutritional factors, 38, 39, 43 that predispose patients to these subtypes.
Although commercial genetic testing is currently available for the ARMS2/HTRA1 locus, it is not recommended that this be used routinely at this time for AMD patients to determine their odds of CNV developing versus GA. The contribution to the overall heritability of advanced AMD subtypes conferred by this locus is relatively small, and all of the genetic and environmental risk factors that contribute to subtype risk remain unknown. Therefore, genetic testing for ARMS2/HTRA1 alone in the clinical setting would give incomplete insight into a particular patient's risk. As more information about additional genetic and environmental risk factors for advanced AMD subtypes are discovered, the ARMS2/HTRA1 genotype could be part of a comprehensive risk score in clinical practice that would affect monitoring schedules or implementation of preventive treatments. The ARMS2/HTRA1 genotype could be used currently in clinical trials for preventive strategies aimed at CNV. Participants with higher-risk genotypes for CNV development could be selected preferentially to improve the power to detect a therapeutic effect, potentially with a shorter follow-up period. 44 A well-powered study looking at all the SNPs that have been associated definitely with overall AMD to date in GWAS is presented herein. Apart from ARMS2/HTRA1, no other new loci reached genome-wide significance for in influencing the risk of one advanced AMD subtype over the other. The recently discovered VEGFA polymorphism 25 was a particularly interesting candidate gene in this analysis, given the important role of vascular endothelial growth factor in the pathogenesis of CNV. However, the OR for the VEGFA polymorphism rs4711751 comparing GA with CNV, including the replication samples, was 1.06 (P ϭ 0.23). Two other known loci (C2 and TIMP3) showed ORs in the CNV versus GA analysis that cannot exclude the possibility of small to modest differences in the magnitude of the association of these loci with each AMD subphenotype. A previous report that found CFH risk alleles were more common in GA cases versus CNV cases could not be confirmed, 22 despite the fact that the current study is much larger and has more power statistically.
There were new variants that had P values at or near genome-wide significance in the discovery cohort that did not have consistent associations in the independent replication samples: rs4755455 (near QSER1) in the CNV versus GA analysis and rs8091635 (BRUNOL4) in the CNV versus no AMD analysis. The inability to replicate these associations could be the result of chance statistical fluctuations in the discovery cohort, insufficient power in the replication cohort, genotyping or imputation imprecision, or heterogeneity between cohorts. Although the sample was the largest to date to evaluate these associations, it was underpowered to detect variants with small effect sizes. To detect an association with a genotype relative risk of 1.10 for one of the AMD subphenotypes with 80% power, approximately 9500 CNV and 9500 GA participants would be needed, assuming a 40% minor allele frequency for the variant (Genetic Power Calculator available at: pngu.mgh.harvard. edu/ϳpurcell/gpc/; accessed June 8, 2011). In contrast, this large GWAS meta-analysis did have sufficient power to document firmly the previous finding from a candidate gene case-control association study. In that prior study, the ARMS2/HTRA1 locus had a moderate effect size with an OR of 1.37 that was quite consistent with the OR of 1.38 observed in this study, 23 suggesting approximately a 38% higher risk of developing CNV versus GA with each T allele a participant harbors.
There were several other novel SNPs with association signals whose P values approached genome-wide significance in the GWAS analyses. For example, rs56209061 in KCTD10 in the CNV versus GA analysis and rs59795197 in ADAM19 in the CNV versus no AMD analysis are SNPs that may be related to advanced AMD subtypes and merit follow-up.
In summary, this study found evidence for genetic susceptibility underlying development of one form of advanced AMD over another. The largest GWAS for advanced AMD subphenotype analysis to date at the onset of the study was performed. The stronger association of the chromosome 10 locus with CNV compared with GA was documented firmly. Several other associated candidate loci for CNV versus GA, GA versus no AMD, and CNV versus no AMD were noted to be worthy of additional follow-up. Larger meta-analysis efforts will be key to increasing power in these subtype analyses and may lead to replication of these loci or identification of additional loci with smaller effect sizes that differ between advanced AMD subtypes.
